Parkinson's disease-like pathology, indicated by a huge reduction of tyrosine hydroxylase as well as by substantially reduced levels and higher elimination rates of DOPAC and HVA, does not result in changes in BBB transport of L-DOPA. Taking the results of this study and that of previous ones, it can be concluded that changes in BBB functionality are not a specific characteristic of Parkinson's disease, and cannot account for the decreased benefit of L-DOPA at later stages of Parkinson's disease.
No takes yet. Share an insight, caveat, or question.
Ravenstijn et al. (2012) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: